Trial of Screening for ALOA-IgG AtheroAbzyme Test

Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01272986

Acronym

OP512011

Enrollment

100

Registered

2011-01-10

Start date

2011-01-31

Completion date

2011-03-31

Last updated

2011-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Myocardial Ischemia

Keywords

Determination of the level of oxidised LDL by measuring the level of IgG in Blood

Brief summary

This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.

Interventions

DEVICEALOA IgG-Elisa

measurement of IgG Level in blood

DEVICEALOA IgG-AtheroAbzyme

measurement of IgG in blood

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Healthy patients * High Risk patients or Asymptomatic myocardial Ischemic patients * Acute Coronary Syndrome patients

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients	Three months

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026